Kura Oncology (NASDAQ:KURA) Issues Earnings Results, Beats Expectations By $0.43 EPS

Kura Oncology (NASDAQ:KURA) announced its quarterly earnings data on Wednesday. The company reported ($0.22) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.65) by $0.43, Zacks reports. The firm had revenue of $53.88 million for the quarter, compared to analyst estimates of $57.96 million.

Kura Oncology Trading Up 2.4 %

Shares of NASDAQ:KURA opened at $7.96 on Thursday. The firm has a market capitalization of $618.77 million, a P/E ratio of -3.35 and a beta of 0.78. Kura Oncology has a 1 year low of $6.98 and a 1 year high of $24.17. The company has a debt-to-equity ratio of 0.02, a current ratio of 11.47 and a quick ratio of 11.47. The business’s 50-day moving average is $8.19 and its 200 day moving average is $13.92.

Insider Activity

In related news, insider Mollie Leoni sold 4,963 shares of the stock in a transaction that occurred on Tuesday, January 28th. The stock was sold at an average price of $7.87, for a total value of $39,058.81. Following the completion of the sale, the insider now owns 88,253 shares of the company’s stock, valued at approximately $694,551.11. This trade represents a 5.32 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, SVP Thomas James Doyle sold 4,949 shares of the firm’s stock in a transaction on Tuesday, January 28th. The stock was sold at an average price of $7.87, for a total value of $38,948.63. Following the sale, the senior vice president now directly owns 88,193 shares of the company’s stock, valued at approximately $694,078.91. This trade represents a 5.31 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 11,729 shares of company stock valued at $92,307 in the last ninety days. Insiders own 5.50% of the company’s stock.

Analyst Ratings Changes

Several research analysts have recently issued reports on KURA shares. TD Cowen reaffirmed a “buy” rating on shares of Kura Oncology in a research note on Thursday, November 21st. Bank of America lowered their price objective on Kura Oncology from $36.00 to $29.00 and set a “buy” rating for the company in a research note on Friday, November 22nd. StockNews.com downgraded shares of Kura Oncology from a “hold” rating to a “sell” rating in a research report on Wednesday, November 20th. Scotiabank lowered their price target on shares of Kura Oncology from $18.00 to $10.00 and set a “sector perform” rating on the stock in a research report on Wednesday, January 8th. Finally, JMP Securities reaffirmed a “market outperform” rating and set a $28.00 target price on shares of Kura Oncology in a report on Thursday, February 6th. One research analyst has rated the stock with a sell rating, three have issued a hold rating, eight have given a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, Kura Oncology currently has a consensus rating of “Moderate Buy” and an average price target of $27.13.

About Kura Oncology

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.